npj Digital Medicine (Aug 2025)
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
- Ulrike Weirauch,
- Markus Kreuz,
- Colin Birkenbihl,
- Miriam Alb,
- Maria Quaranta,
- Laurence Calzone,
- Sophia Orozco-Ruiz,
- Stefanie Binder,
- Luise Fischer,
- Solène Clavreul,
- Morine Maguri,
- Maximilian Ferle,
- Michael Rade,
- Guillaume Azarias,
- Jay R. Hydren,
- Jakub Jamarik,
- Daniel Schwarz,
- Zsolt Sebestyen,
- Jurgen Kuball,
- Georg Popp,
- Chloé Antoine,
- Manon Knockaert,
- Clara T. Schoeder,
- David Fandrei,
- Carmen Sanges,
- Vaclovas Radvilas,
- Nico Gagelmann,
- Markus Rückert,
- Olaf Penack,
- Stephan Fricke,
- Andreas Schmidt,
- Carol Ward,
- Carl Steinbeisser,
- Jean-Marc Van Gyseghem,
- Anna Niarakis,
- Laurent Garderet,
- Michael Hudecek,
- Thomas Neumuth,
- Uwe Platzbecker,
- Ulrike Köhl,
- Regina Demlova,
- Andreas Kremer,
- Stefan Franke,
- Holger Fröhlich,
- Maximilian Merz,
- Kristin Reiche,
- On behalf of the CERTAINTY Consortium
Affiliations
- Ulrike Weirauch
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Markus Kreuz
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Colin Birkenbihl
- Fraunhofer Institute for Algorithms and Scientific Computing SCAI
- Miriam Alb
- Department of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg
- Maria Quaranta
- Information Technology for Translational Medicine (ITTM) S.A.
- Laurence Calzone
- Institut Curie, INSERM, U 1331, Mines Paris Tech, PSL Research University
- Sophia Orozco-Ruiz
- Institut Curie, INSERM, U 1331, Mines Paris Tech, PSL Research University
- Stefanie Binder
- Institute for Clinical Immunology, University Hospital of Leipzig
- Luise Fischer
- Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital of Leipzig
- Solène Clavreul
- Myeloma Patients Europe AISBL
- Morine Maguri
- Myeloma Patients Europe AISBL
- Maximilian Ferle
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Michael Rade
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Guillaume Azarias
- TriNetX Oncology GmbH
- Jay R. Hydren
- HealthTree Foundation Inc.
- Jakub Jamarik
- CREATIC, Faculty of Medicine, Masaryk University
- Daniel Schwarz
- CREATIC, Faculty of Medicine, Masaryk University
- Zsolt Sebestyen
- Center for Translational Immunology and Department of Hematology, University Medical Center Utrecht, Utrecht University
- Jurgen Kuball
- Center for Translational Immunology and Department of Hematology, University Medical Center Utrecht, Utrecht University
- Georg Popp
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Chloé Antoine
- Research Center Information, Law and Society, University of Namur
- Manon Knockaert
- Research Center Information, Law and Society, University of Namur
- Clara T. Schoeder
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- David Fandrei
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Carmen Sanges
- Department of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg
- Vaclovas Radvilas
- European Society for Blood and Marrow Transplantation (EBMT)
- Nico Gagelmann
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf
- Markus Rückert
- TriNetX Oncology GmbH
- Olaf Penack
- Department of Hematology, Oncology and Tumorimmunology, Charité—Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin
- Stephan Fricke
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Andreas Schmidt
- Singleron Biotechnologies GmbH
- Carol Ward
- F. Hoffmann-LaRoche AG
- Carl Steinbeisser
- Collaborate Project Management
- Jean-Marc Van Gyseghem
- Research Center Information, Law and Society, University of Namur
- Anna Niarakis
- Molecular, Cellular and Developmental Biology Unit (MCD), Centre de Biologie Integrative (CBI), University of Toulouse, UPS, CNRS
- Laurent Garderet
- Hematology and Cellular Therapy Department, Hopital Pitié Salpêtrière APHP, Sorbonne Université
- Michael Hudecek
- Department of Internal Medicine II, Chair of Cellular Immunotherapy, University Hospital Würzburg
- Thomas Neumuth
- Innovation Center Computer Assisted Surgery, Universität Leipzig
- Uwe Platzbecker
- Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital of Leipzig
- Ulrike Köhl
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Regina Demlova
- CREATIC, Faculty of Medicine, Masaryk University
- Andreas Kremer
- Information Technology for Translational Medicine (ITTM) S.A.
- Stefan Franke
- Innovation Center Computer Assisted Surgery, Universität Leipzig
- Holger Fröhlich
- Fraunhofer Institute for Algorithms and Scientific Computing SCAI
- Maximilian Merz
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- Kristin Reiche
- Fraunhofer Institute for Cell Therapy and Immunology IZI
- On behalf of the CERTAINTY Consortium
- DOI
- https://doi.org/10.1038/s41746-025-01809-6
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Abstract In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for engineered ACIs (eACI-VTs) to model the complex interplay between cell product and patient physiology. We motivate utilizing VTs in eACIs to provide decision support and reflect on how eACI-VTs can support the widespread use of eACIs.
